Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Excitotoxity, primarily mediated by excessive glutamate release, is one of the main proposed mechanisms for neurodegeneration in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis.1 However, a few clinical trials of medications with glutamate-blocking properties have not yet shown beneficial effects in patients with MS.
Fatigue is one of the most frequently reported MS symptoms and the underlying mechanisms of this potentially debilitating symptom are not well understood.2 Here, we report the effects of riluzole, a medication with glutamate-blocking properties, on fatigue in a randomized clinical trial in patients with early MS.
Nourbakhsh B, Revirajan N, Waubant E. Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis. JAMA Neurol. 2015;72(11):1374-1375. doi:10.1001/jamaneurol.2015.2332